



Average FY Product Sales Consensus

€m	2021a	2022e	2023e	2024e	2025e	2026e	2027e	Peak Sales	NPV*
Product Portfolio									
Cimzia	1,841	2,021	2,052	1,966	1,730	1,414	1,129		4,625
Vimpat	1,549	1,043	595	487	421	375	348		1,631
Keppra	970	719	631	576	539	503	484		2,107
Briviact	355	461	542	605	669	590	389	657	1,746
Neupro	307	287	261	230	212	198	183		795
Evenity**		774	956	1,100	1,220	1,275	1,280	1,696	
Nayzilam	57	83	111	137	156	165	159	201	476
Bimzelx	4	49	230	591	984	1,371	1,718	3,017	5,968
Fintepla		111	244	361	482	577	615	803	1,970
Potential new products**									
Zilucoplan		0	43	160	289	434	581	983	1,916
Rozanolixizumab (Rozimab)		0	27	105	210	333	426	917	1,629
Dapimab		0	0	4	36	125	144		
Staccato alprazolam		0	2	15	47	87	133	331	498
Bepranemab		0	0	11	43	64	45		

* If NPV cell blank: not sufficient data available

**global sales, non-risk adj.

Median FY Product Sales Consensus

€m	2021a	2022e	2023e	2024e	2025e	2026e	2027e	Peak Sales	NPV*
Product Portfolio									
Cimzia	1,841	2,043	2,063	1,962	1,670	1,385	1,123		4,564
Vimpat	1,549	1,046	594	505	449	405	378		1,627
Keppra	970	717	633	578	534	497	473		1,867
Briviact	355	469	543	608	665	605	355	651	1,736
Neupro	307	295	267	230	201	194	178		673
Evenity**		762	966	1,116	1,242	1,245	1,324	1,426	
Nayzilam	57	81	113	136	156	160	168	180	500
Bimzelx	4	46	237	590	938	1,280	1,716	2,850	5,376
Fintepla		112	239	372	498	600	634	800	1,694
Potential new products**									
Zilucoplan		0	52	176	304	423	633	1,000	1,995
Rozanolixizumab (Rozimab)		0	26	93	189	300	412	1,000	1,300
Dapimab		0	0	0	50	100	112		
Staccato alprazolam		0	0	9	30	60	113	255	529
Bepranemab		0	0	0	27	27	40		

* If NPV cell blank: not sufficient data available

**global sales, non-risk adj.

Based on the estimates of 15 brokers

Last updated: 16/09/22